Cargando…

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy

AIM: Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene expression prof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahni, Sumit, Nahm, Christopher, Ahadi, Mahsa S., Sioson, Loretta, Byeon, Sooin, Chou, Angela, Maloney, Sarah, Moon, Elizabeth, Pavlakis, Nick, Gill, Anthony J., Samra, Jaswinder, Mittal, Anubhav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523964/ https://www.ncbi.nlm.nih.gov/pubmed/37533202 http://dx.doi.org/10.1002/cam4.6411

Ejemplares similares

Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single‐cell analysis
por: Byeon, Sooin, et al.
Publicado: (2023)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2020)

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer
por: Nahm, Christopher B., et al.
Publicado: (2022)

The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma
por: Tayao, Michael, et al.
Publicado: (2016)

The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients’ survival
por: Jambor, Maxwell A., et al.
Publicado: (2022)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
por: Maloney, Sarah, et al.
Publicado: (2021)

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Drain fluid biomarkers for prediction and diagnosis of clinically relevant postoperative pancreatic fistula: A narrative review
por: Rykina-Tameeva, Nadya, et al.
Publicado: (2022)

Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
por: Gillson, Josef, et al.
Publicado: (2022)

Postoperative pancreatic fistula: a review of traditional and emerging concepts
por: Nahm, Christopher B, et al.
Publicado: (2018)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis
por: Stephenson, David, et al.
Publicado: (2017)

Drain fluid biomarkers for the diagnosis of clinically relevant postoperative pancreatic fistula: a diagnostic accuracy systematic review and meta-analysis
por: Rykina-Tameeva, Nadya, et al.
Publicado: (2023)

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
por: Andrici, Juliana, et al.
Publicado: (2015)

Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis
por: Li, Angela E., et al.
Publicado: (2013)

Surgical management of high-grade pancreatic injuries: Insights from a high-volume pancreaticobiliary specialty unit
por: Chui, Juanita Noeline, et al.
Publicado: (2023)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
por: Kim, Hyung Sun, et al.
Publicado: (2021)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
por: Andrici, Juliana, et al.
Publicado: (2016)

Do you get the GIST? Successful resection of a giant 3.5 kg gastrointestinal stromal tumour
por: Borruso, Luca, et al.
Publicado: (2022)

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
por: Wong, Matthew H., et al.
Publicado: (2016)

Safety and Efficacy of Pancreaticoduodenectomy in Octogenarians
por: Huang, Yeqian, et al.
Publicado: (2021)

Granular cell tumour of the pancreas: a case report and systematic review
por: Tree, Kevin, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review
por: Brown, Kai M., et al.
Publicado: (2016)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion
por: Ofri, Adam, et al.
Publicado: (2022)

Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
por: Schorn, S., et al.
Publicado: (2018)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
por: Zhang, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h19bd41ruc95i7bslsnjgmp23s